Anticoagulant choice in antiphospholipid syndrome–associated thrombosis


Background: DOACs have largely replaced VKAs as first-line therapy for venous thromboembolism in patients with adequate renal function. However, there is concern in APS that DOACs may have higher rates of recurrent thrombosis than VKAs when treating thromboembolism.

Dr. David Portnoy, division of hospital medicine, Mount Sinai Health System, New York

Dr. David Portnoy

Study design: Randomized noninferiority trial.

Setting: Six teaching hospitals in Spain.

Synopsis: Of adults with thrombotic APS, 190 were randomized to receive rivaroxaban or warfarin. Primary outcomes were thrombotic events and major bleeding. Follow-up after 3 years demonstrated new thromboses in 11 patients (11.6%) in the DOAC group and 6 patients (6.3%) in the VKA group (P = .29). Major bleeding occurred in six patients (6.3%) in the DOAC group and seven patients (7.4%) in the VKA group (P = .77). By contrast, stroke occurred in nine patients in the DOAC group while the VKA group had zero events, yielding a significant relative RR of 19.00 (95% CI, 1.12-321.90) for the DOAC group.

The DOAC arm was not proven to be noninferior with respect to the primary outcome of thrombotic events. The higher risk of stroke in this group suggests the need for caution in using DOACs in this population.

Bottom line: DOACs have a higher risk of stroke than VKAs in patients with APS without a significant difference in rate of a major bleed.

Citation: Ordi-Ros J et. al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome. Ann Intern Med. 2019;171(10):685-94. doi: 10.7326/M19-0291.

Dr. Portnoy is a hospitalist in the Division of Hospital Medicine, Mount Sinai Health System, New York.

Recommended Reading

Study gives bleeding risk estimates for VTE patients on anticoagulants
The Hospitalist
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
The Hospitalist
CVST after COVID-19 vaccine: New data confirm high mortality rate
The Hospitalist
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
The Hospitalist
Autopsy findings reveal venous thromboembolism in patients with COVID-19
The Hospitalist
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
The Hospitalist
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The Hospitalist
Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE
The Hospitalist
Apixaban outmatches rivaroxaban for VTE in study
The Hospitalist
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
The Hospitalist
   Comments ()